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FROM:  
A/Prof. Mary Bebawy 
Graduate School of Health 
University of Technology Sydney 
PO Box 123 – Broadway 
NSW 2007 Australia 
mary.bebawy@uts.edu.au  
 
TO:  
Prof. Enrico Clementi 
Editor-in-Chief – Pharmacological Research 
 
 
 
Dear Prof. Clementi, 
 
I am pleased to submit a review paper, on behalf of co-authors, entitled “Circulating Tumor DNA - current 
state of play and future perspectives” by Mr. Gabriele De Rubis, Dr. Sabna Rajeev Krishnan, Prof. Michael 
Wallach and A/Prof. Mary Bebawy, for consideration for publication in Pharmacological Research. 
 
In this manuscript we describe the current status and the exciting future perspectives of the use of 
circulating tumor DNA (ctDNA) as liquid biopsy for cancer diagnosis, screening, routine monitoring, 
prognostication and pharmacological treatment selection. We discuss the different types of information 
obtainable by analyzing ctDNA and their clinical implications. We also detail the most innovative 
technologies developed for ctDNA analysis, and the future progresses needed to overcome the current 
limitations in this field. 
 
We believe that this manuscript is appropriate for publication by Pharmacological Research because the 
liquid biopsy field is currently an extremely relevant topic in targeted cancer therapy, precision medicine 
and personalized therapy. Liquid biopsies overcome the limitations of current golden standards for cancer 
screening and molecular characterization (i.e. tissue biopsies) and, thanks to their low-to –null invasiveness 
and repeatability, are set to revolutionize the current paradigms of cancer management. ctDNA in particular 
is, as of today, the most deeply characterized among the different components of a liquid biopsy. This is 
demonstrated by the very recent approval, by the US FDA, of the first companion diagnostic based on the 
analysis of ctDNA (cobas EGFR Mutation Test v2 – Roche) and by the large number of clinical studies and 
                                                                                 
clinical trials being currently conducted and having the study of ctDNA among the primary outcome 
measures. Considering the high-level reputation of Pharmacological Research and its commitment to share 
the knowledge on cutting-edge topics among specialists in different disciplines, we believe that this is the 
journal that mostly suits our review for publication. 
 
We state that this manuscript has not been published and is not under consideration for publication 
elsewhere.  We also declare no conflicts of interest to disclose. 
 
 
Thank you for your consideration! 
 
Sincerely, 
 
A/Prof. Mary Bebawy 
Comments from the editors and reviewers:
-Reviewer 1
  - 
P2  The term ‘liquid biopsies’ could be defined   Done
there are multiple types of constituents.  We define them in the Introduction (Page 5, lines 82-84) 
and in Figure 1
  Why does ctDNA have the greatest potential?  We don’t state that ctDNA has the greatest 
potential, but that it has “tremendous capability”, and that it is the most widely characterized 
(especially with regards to the FDA-approvals of ctDNA-based diagnostic tests, see throughout text)
 
P4  Replace ‘progresses’ with ‘advances’ through the text. Done
The use of a single marker is prone to error, the trend is to use patterns of markers to make 
diagnoses.  Done (Lines 62-63) 
 
P5  The term ‘Darwinian evolution’ seems out of place; mention selective pressure on tumours to 
grow.  Done
Why are ctDNA the preferred markers? we recognize that stating that ctDNA is “the most promising 
component” of the circulome might be misleading. We changed the sentence in Line 84 from 
“Among these, ctDNA is the most promising and extensively studied component of the Tumor 
Circulome” to “Among these, ctDNA is the most extensively characterized component of the Tumor 
Circulome”
What is the half-time for ctDNA in the circulation,  We mention it at Page 8, Line 148
provide a size distribution curve.  authors do not see this necessary to include
Do the differential ctDNA encode tumour drivers?  We mention  driver mutations in Pag. 6 Line 114.
 
P7  Could rearrangement of DNA occur after cell death? Not known.  Authors do not see relevant to 
include
 
P8  Some ctDNA must be more stable in the circulation?  Exosome-associated DNA is more stable in 
circulation: we discuss this in Paragraph 2.3 (P13)
 
P9  Methylation sites will be more variable than ctDNA sequences.   Current literature says the 
opposite. mutations, compared to methylations, are more variable and show lower consistency 
within the same tumor. Furthermore, the high diversity of mutations are often spread over several 
exons of the same gene. (Warton K et al. 2015, Front Mol Biosci, doi: 10.3389/fmolb.2015.00013)
 
P10  You could use the development of KRAS as a marker from 1994 as a an example   Done (see 
Lines 200-201)
Note that patterns of markers are now preferred.  Done (Pag. 11, Lines 214-217)
 
P11  Provide some examples of calculation of differential mutant allele frequencies (MAF) found in 
ctDNA.   Not Relevant – a practical example of MAF calculation is unnecessary in this section. We 
define the MAF earlier in the text (Line 128)
 
P13  Is ctDNA protected from degradation in extra-cellular vesicles? Done Pag. 14 Lines 290-292
 
P15  Levels of leukocyte subtypes change in cancers, is this mixture of markers a problem? 
Leukocyte-derived DNA contamination is an issue because it “dilutes” ctDNA with wild-type copies of 
the genes of interest, further reducing the MAF (Lines 398-402). Therefore, the relative leukocyte 
subtype composition is irrelevant for the purpose of ctDNA mutation analysis
 
P16  Is bacterial DNA in stool samples a problem?   We couldn’t find any literature about the 
possible influence of bacterial DNA in stool cancer biomarker analysis
 
P19  Early detection is crucial for curing cancer, what is the sensitivity of the best method for 
analysing ctDNA?  Done (Line 432)
 
Replace Figure 1 with a detailed workflow for the best method for analysis of multiple ctDNA from a 
blood sample.   We don’t agree with this suggestion. The authors request Figure 1 remain as it 
displays the different components of the Tumor Circulome and is used to highlight the 
representativeness of the tumor heterogeneity held by liquid biopsies
 
Include reference:  Shu et al., (2017) Scientific Reports 7: 583  Done (Line 245)
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Circulating Tumor DNA – current state of play and future 
perspectives
Abstract:
Cancer management paradigms are shifting towards a personalized approach thanks 
to the advent of the -omics technologies. Liquid biopsies, consisting in the sampling of 
blood and other bodily fluids, are emerging as a valid alternative to circulating tumor 
biomarkers and tumor tissue biopsies for cancer diagnosis, routine monitoring and 
prognostication. The content of a liquid biopsy is referred to as the “tumor circulome”. 
Among its components, circulating tumor DNA (ctDNA), including both cell-free and 
exosome-associated DNA, is the most widely characterized element. ctDNA analysis 
has a tremendous capability in the diagnostic arena. Its potential has been 
demonstrated at each level of disease staging and management and supported by a 
recent FDA approval for companion diagnostic, and the investments being made by 
pharmaceutical companies in this sector are numerous. The approaches available for 
ctDNA analysis allow both quantitative and qualitative studies and range from PCR 
and dPCR-mediated single/multiple gene mutational assessment to whole genome 
next generation sequencing and methylation mapping. Although the principal object of 
a liquid biopsy is blood, other body fluids such as urine and saliva show potential as 
complementary DNA sources for tumor analysis. In this review we provide a synopsis 
on the state of play of current ctDNA application. We discuss the clinical significance 
of ctDNA analysis and review the state of the art of technologies being currently 
developed to this aim. We also discuss the current issues limiting ctDNA application 
and highlight the promising approaches being developed to overcome these.
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1. Liquid Biopsy – a revolutionary approach to diagnosis and disease state 
management 
Cancer is the major cause of morbidity and mortality worldwide, as it has been 
estimated that 14.1 million new cancer cases have been diagnosed and that cancer 
caused 8.4 million deaths in 2012 [1]. During the last decades, enormous advances 
have been made in the study and dissection of tumors’ molecular characteristic, 
thanks also to the advent of the –omics era, and these advances have led to the birth 
of precision oncology as a branch of precision medicine [2, 3], shifting from a “one size 
fits all” therapeutic approach towards the identification of “the right treatment, for the 
right patient, at the right time”. The applications of tumor molecular profiling 
encompass all the stages of cancer management, including early detection/screening, 
prognosis, patient stratification for predicting response to therapy and for the selection 
of personalized therapies, monitoring of treatment effectiveness and response and 
follow-up for the early detection of relapse and metastasis occurrence [4]. The two 
main instruments that are still used by clinicians to assess these goals are the use of 
circulating tumor-derived protein markers and tumor tissue biopsies.
Protein markers have been extensively used for cancer screening (e.g. the PSA – 
Prostate Specific Antigen - protein for prostate cancer) [5] or for postoperative follow-
up of recurrence (e.g. CA 15-3 for breast cancer) [6] and, although they allow a 
longitudinal monitoring of cancer patients, their real clinical value is still highly debated. 
As single biomarkers generally have low sensitivity and specificity, the use of panels 
of markers is a current trend [7]. In particular, with regards to routine PSA screening, 
its net benefit has proven to be marginal in terms of mortality reduction, while the 
harms associated to overdiagnosis and to the side effects of standard therapies are 
considerable [5]. Furthermore, the use of CA 15-3 for post-operative follow up lacks 
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evidence of benefit in terms of patient outcome or quality of life. Further, it is only 
recommended for supportive application in the evaluation of chemotherapeutic 
response, particularly in poorly accessible disease [6]. Tissue biopsies, although 
currently representing the standard procedure for tumor diagnosis, have two main 
disadvantages: first of all, they are invasive procedures, which very often cause 
complications [8] and in most cases don’t allow longitudinal monitoring of patients [9]; 
secondly, they are virtually never representative of the tumor heterogeneity and 
multiclonality generated by the selective pressure to which the tumor is subjected 
during its growth [9, 10].
As a favourable alternative to tissue biopsies, during the last years the concept of 
“liquid biopsy”, consisting in the sampling of non-solid biological tissues, blood in 
primis, gained an exceptional momentum and is becoming a topical concept in 
precision oncology [9]. The content of a liquid biopsy is an instantaneous snapshot of 
what we define “the Tumor Circulome”. It comprises a subset of tumor-derived factors, 
circulating in the bloodstream, which can be directly or indirectly used as a source of 
tumor biomarkers [11]. These include circulating proteins, cell-free circulating tumor 
DNA (ctDNA) and RNAs, circulating tumor cells (CTCs), tumor extracellular vesicles, 
and tumor-educated platelets (TEPs) (Figure 1). Among these, ctDNA is the most 
extensively characterized component of the Tumor Circulome as of today, and it is the 
only component on which an FDA (Food and Drug Administration)-approved 
companion diagnostic test is based [12]. The potential applications of ctDNA in cancer 
management have just started to be explored, and we retain very likely that ctDNA will 
become the protagonist in the development of novel companion and complementary 
diagnostics. This review provides an up-to-date synopsis of the current state of the 
use of ctDNA as liquid biopsy in cancer management. We discuss the current clinical 
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applications of ctDNA in cancer diagnostics and disease state management and the 
exciting future perspectives, but also the current limitations, on the use of this 
component of the Tumor Circulome in liquid biopsies. We also detail the analytical 
technologies required and advances made in purification and analysis of ctDNA.
2. Circulating Tumor DNA - a key player in the liquid biopsy arena. 
ctDNA is the fraction of circulating cell-free DNA (cfDNA) that originates from tumor 
cells. It consists of fragmented DNA, between 80 and 200 bp (base pairs) in length, 
with peaks of length corresponding to multiples of the canonical nucleosome-
associated DNA length (147 + 20-90 bp) [13]. The presence of circulating cfDNA was 
first reported 70 years ago [14] and, in healthy individuals, hematopoietic cells 
represent the major source of cfDNA [15].
The early association between malignancy and cfDNA levels came about from clinical 
reports of patients with malignant disease having higher levels of cfDNA compared to 
patients with benign diseases [16]. This was followed by work conducted by Stroun 
and colleagues in 1989 which traced the neoplastic origin of such DNA present in the 
plasma of oncologic patients [17]. The mechanism by which ctDNA is released in 
circulation is not entirely known. Apoptosis and necrosis of cancer cells are thought to 
be the major contributors [18, 19]. Other possibilities include active secretion of DNA 
by tumor cells [20] as well as potential if not minor contributions from CTCs [21].
The potential for using ctDNA as cancer biomarkers for disease screening were first 
published in the mid-nineties with the identification of mutations in the driver gene 
KRAS in the ctDNA isolated from colorectal and pancreatic cancer patient blood 
samples [22-25]. The clinical utility in identifying mutations associated with the onset 
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or recurrence of cancer in ctDNA became immediately obvious. Since these early 
studies, during the last two decades numerous tumor-associated mutations have been 
identified in ctDNA for different types of cancers, including colorectal, breast, ovarian, 
pancreatic and lung cancer [21].
2.1.  What does ctDNA analysis tell us?
By analyzing ctDNA it is possible to obtain two broad classes of information: 
quantitative and qualitative or genomic information, on the patients’ disease state [26]. 
Quantitative information in the context of gauging tumor burden has application in 
disease staging, treatment response and relapse monitoring, minimal residual disease 
(MRD) detection and prognostication. This type of information derives from the 
measurement of ctDNA concentration, expressed as mutant allele concentration 
(copies / volume of plasma) or mutant allele fraction (MAF, proportion of mutant allele 
in a given locus). This quantitative capacity of ctDNA has been applied across many 
different cancers and has been shown to correlate with tumor stage [27], tumor volume 
and, indirectly, with time to progression after chemotherapy [28]. Expanding on this, 
an interesting prospective study published by Tie et al. in 2016 demonstrated, in 
patients with colorectal cancer, that the detection of ctDNA after surgical resection of 
tumor strongly correlated with recurrence of disease within three years [29].
Genomic or qualitative information consists of profiling of mutations, amplifications, 
deletions and translocations in ctDNA, in selected loci or across the whole genome. 
This type of information may provide identification of resistance-related mutations, 
thus supporting treatment selection. The identification of genetic alterations 
associated with drug resistance or drug sensitivity through ctDNA is of crucial 
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importance in cancer management, especially considering that the emergence of 
acquired drug resistance is believed to be the cause of treatment failure in 90% of 
patients with metastatic disease [30]. It also has application in monitoring the clonal 
evolution of the tumor over time and supporting decision making for “adaptive or 
reactive” strategies. This approach entails continuous patient follow-up after surgery 
and/or treatment, monitoring for new resistance mutations arising from the adaptation 
of tumor subclones in response to treatment [31], and finally, in the adjustment of the 
therapeutic regimen accordingly [26]. The relevance of this process is supported by 
the short half-life of ctDNA (approximately 1.5h [32]), which provides an “instantaneous 
snapshot” of tumor mutational state at the time of detection. An excellent example of 
this strategy is the study published by Siravegna and colleagues in 2015 [33], in which 
they continuously monitored the clonal evolution of disease in metastatic colorectal 
cancer (mCRC) patients through ctDNA mutational profiling and demonstrated that 
levels of mutant RAS clones, which rise in blood during EGFR blockade and are at the 
root of anti-EGFR therapy resistance, drop after anti-EGFR therapy interruption thus 
restoring, at least partially, drug sensitivity. This study provided a rationale for the 
efficacy of re-challenge anti-EGFR therapy [33].
The first ctDNA companion diagnostic test for the identification of EGFR mutations in 
non-small-cell lung cancer (NSCLC) patients (cobas® EGFR Mutation Test v2 – 
Roche Diagnostics) has been recently approved by FDA [12]. The aim of this test is to 
guide the use of EGFR-Tyrosine Kinase Inhibitors (EGFR-TKI) based on the presence 
of specific mutations, in the event that a solid biopsy of the tumor is not available. A 
newly emerging application of this test is currently the detection of the T790M mutation 
for the use of the third generation EGFR-TKI Osimertinib, and the feasibility of this 
approach has been recently validated by different studies, including a phase III clinical 
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trial [34, 35]. A similar diagnostic test, therascreen EGFR Plasma RGQ PCR Kit 
(Qiagen), has been approved by the CE as In Vitro Diagnostic test in 2015 [36]. At the 
moment, several clinical studies are ongoing to evaluate the clinical utility of ctDNA 
analysis across different types of cancer and the investments being made by 
pharmaceutical companies in this sector are numerous. Relevant examples of these 
studies are summarized in Table 1 and Table 2.
Other qualitative information obtainable by ctDNA analysis is the identification of 
tumor-specific epigenetic/epigenomic variations, which include ctDNA methylation and 
histone post-translational modifications (PTMs) in circulating cell-free nucleosomes 
[37]. The first report detailing the feasibility of detecting tumor-associated aberrant 
ctDNA methylation was by Wong et colleagues in 1999 [38]. The team compared the 
methylation status of the p16 gene in ctDNA and in tumor-derived DNA, finding a 
concordance of 81%. Since then, numerous studies have been conducted with the 
aim of characterizing the potential use of ctDNA methylation as biomarkers for the 
early diagnosis and prognosis of cancer, for cancer screening, and for real-time follow 
up of tumor dynamics [39-41]. One potential advantage of the analysis of ctDNA 
methylation compared to the analysis of mutations and rearrangements is that 
changes in DNA methylation in cancer have greater consistency than mutations, and 
are usually concentrated in narrower regions of each gene (for example, CpG islands). 
As a consequence, potentially, smaller proportions of the genome could be analysed 
for methylation to provide a test of adequate sensitivity [41]. An important milestone in 
the area of ctDNA methylation analysis has been the approval by the FDA in 2016 of 
Epi proColon®, a screening test for colorectal cancer, based on the analysis of the 
methylation of the SEPT9 promoter region [42]. Another important potential application 
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of ctDNA methylation analysis is the identification of the tissue of origin in cancers of 
unknown primary [43].
2.2.  Technological approaches to ctDNA analysis
The technologies available for ctDNA analysis are numerous and encompass a scale 
which ranges from single mutation detection to genome-wide analysis. They are 
schematically represented in Figure 2.
With regard to the identification of sequence alterations (mutations, copy number 
variations and chromosome rearrangements), the analytical approaches can be 
divided in PCR-based and Next-Generation Sequencing (NGS)-based techniques. 
PCR-based techniques are used for single-locus or in multiplexed assays and were 
historically the first to be used, with allele-specific PCR being used in 1994 for the 
identification of mutant KRAS in pancreatic carcinoma [25]. The cobas® EGFR 
Mutation Test v2 uses this approach in a real-time PCR context, while the therascreen 
EGFR Plasma RGQ PCR Kit is based on a variation of this technique called 
Amplification-Refractory mutation system PCR (ARMS-PCR). Although useful, allele-
specific PCR has very limited analytical sensitivity [26] and it is currently being 
substituted by more sensitive approaches. Among those, digital PCR (dPCR) [44-46] 
and its variants droplet digital PCR (ddPCR) [47, 48] and BEAMing (Beads, Emulsion, 
Amplification, Magnetics) [49] are being successfully used for ctDNA analysis. These 
techniques approach sensitivities ranging between 0,001% and 0,01% MAF [50] and 
have the advantage, compared to traditional qPCR, to offer an absolute quantification 
of the number of mutant alleles in a sample [51]. Although dPCR-based approaches 
have high sensitivity and absolute quantification as important points of strength, an 
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important limitation of these approaches relies in the fact that they are applicable for 
the analysis of a limited number of mutation hotspots at the same time. This is an 
important issue: as single mutations or small panels may not be informative, the study 
of patterns of mutations has a higher predictive value and it is a preferable approach 
[26].
NGS-based techniques have the important feature that they can also be used to 
identify de novo mutations, and they can be divided into two subcategories basing on 
the extent of genomic coverage, namely targeted sequencing and genome-wide 
sequencing techniques. Targeted sequencing involves the sequencing of specific loci 
(from individual exons to the whole exome) after selective amplification by PCR 
(amplicon-based) or hybrid capture-based enrichment. It has the advantage of 
interrogating a larger number of loci compared to dPCR-based approaches, although 
with higher costs, longer times and generally lower sensitivity [4].
Among the amplicon-based technologies, Enhanced Tagged Amplicon-Sequencing 
(eTAm-Seq™ - Inivata Ltd) is worth noting in that it has been recently used to develop 
and validate the InVision™ liquid biopsy analytical platform, which is capable of 
detecting mutant alleles down to a MAF of 0.02% with high reproducibility [52]. A 
similar technology is the Ion AmpliSeq™ platform (ThermoFisher Inc.), which has 
recently been used to assess mutations in a large panel of genes in lung cancer 
patients. The results obtained were then validated using ddPCR [53].
Hybrid-capture based technologies allow the selection and sequencing of a number of 
target sequences ranging from panels of genes to the whole exome (WES, Whole 
Exome Sequencing). WES has been recently used, paired with deep coverage 
targeted sequencing, to study clonal heterogeneity in neuroblastoma, in an elegant 
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study in which somatic mutations and copy number alterations were compared 
between solid biopsy and cfDNA [54]. In another study, Manier and colleagues used 
WES to compare the mutational landscape and the copy number alteration profile 
between CTCs, cfDNA and matched tumor biopsies, obtaining high concordance 
between the different classes of biopsy [55]. Usually, for the same cost, the sensitivity 
of hybrid capture-based approaches is inversely proportional to the number of loci 
analysed [4] and, generally, WES limit of detection is around 5% MAF [26]. In order to 
enhance the sensitivity, patient-specific or cancer-specific assays can be designed 
including only genes of interest with an important prognostic or diagnostic value [56]. 
An example of this approach is the very recent CAPP-Seq (Cancer Personalized 
Profiling by deep Sequencing) [57] technology, which has been used for the early 
detection of MRD [58] and the investigation of tumor heterogeneity in lung cancer [59], 
as well as in diffuse large B cell lymphoma [60] and leiomyosarcoma [61].
In order to improve the sensitivity of sequencing techniques, recently the use of Unique 
Molecular Identifiers (UMIs) has been adopted: this approach consists in tagging each 
template molecule with a “molecular barcode”, a unique sequence, during the library 
preparation phase. In this way, for each template molecule, a consensus sequence is 
obtained, thus drastically reducing the background noise generated by the random 
errors occurring during the PCR amplification step [62]. This approach is used in both 
the above-described eTAm-Seq™ and Ion AmpliSeq™ technologies. Another 
example of the use of UMIs is the Simple, multiplexed, PCR-based barcoding of DNA 
for sensitive mutation detection using sequencing (SiMSen-Seq) technology [63]. 
Moreover, considering that ctDNA is slightly shorter than non-tumor cfDNA, this 
difference can be exploited for the in vitro or in silico concentration of ctDNA, thus 
further increasing the sensitivity of the following tests [26, 64, 65]. Another recently 
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
Page 13 of 29
developed methodology to concentrate mutant DNA is the Nuclease-assisted Minor-
allele Enrichment with Probe-Overlap (NaME-PrO), which is based on the selective 
digestion of wild-type alleles through the use of a double stranded DNA-specific 
nuclease guided on the target sequence by selective oligonucleotide probes that pair 
with wild-type alleles of the genes of interest. This approach enables mutation 
detection at 0.01 - 0.00003% MAF [66].
Approaches for t he identification of copy number alterations from ctDNA are usually 
genome-wide, and they include Array-Comparative Genome Hybridization (Array-
CGH) [67] and low coverage whole genome sequencing, such as shallow whole 
genome sequencing (sWGS) [68] and Plasma-Seq [69]. Moreover, a suitable 
technique for the identification and quantification of chromosomal translocations is the 
Personalized Analysis of Rearranged Ends (PARE), a PCR-based approach 
consisting in the use of primers spanning translocation breakpoints previously 
identified via NGS [70].
Finally, with regards to the analysis of ctDNA methylation, the methodologies used 
range from single-locus to genome-wide and are mostly based on bisulphite 
conversion of non-methylated cytosines. They involve methylation-specific PCR, the 
use of methylation-sensitive restriction enzymes, array based hybridization, and 
bisulphite sequencing [39].
2.3.  Exosomal DNA (exoDNA)
Another important source of circulating tumor-derived DNA is the fraction contained 
within circulating extracellular vesicles (EVs). EVs are membranous particles released 
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from all cell types in physiological and pathological conditions, as well as following 
different types of stimuli. They can be found in almost every body fluid, especially in 
blood [71, 72]. Once considered inert elements of “cell debris”, or as a simple means 
to eliminate unneeded components from the cytoplasm of cells [73, 74], during the last 
decade EVs have been recognized as fundamental mediators of intercellular 
communication [75]. The fact that EVs shield their molecular cargo from degradation, 
increasing its stability, makes EV-associated DNA a potentially favourable alternative 
to cell-free DNA [76]. Although EVs, exosomes in particular, are well recognized as an 
important novel component of the tumor circulome suitable for biomarker analysis, 
most of the efforts until now have been made in exploring their protein and RNA 
(mRNA and miRNA) content [77-79] and very few studies have been focused on the 
analysis of their DNA cargo. The first paper describing the feasibility of the analysis of 
exosomal DNA as liquid biopsy was published in 2014 [80]. In this study, the authors 
demonstrated that exosomes derived from both cancer cell lines and the serum of 
pancreatic cancer patients contain long DNA fragments (> 10 kb) harbouring tumor-
characteristic mutations, and that these DNA fragments where uniformly 
representative of nuclear genomic DNA, with reads spanning across all chromosomes 
[80]. Similar results were obtained independently the same year on exosomes derived 
from different cancer cell lines [81]. In a successive study, San Lucas and colleagues 
performed a comprehensive NGS profiling of exoDNA and exoRNA isolated from 
pleural effusion- or plasma- derived exosomes of three patients with pancreaticobiliary 
cancers [76]. The results obtained demonstrated that a wide number of biomarkers 
could be detected by profiling exosomal nucleic acids, including point mutations, copy 
number variations and gene fusions. Interestingly, in this study an unexpected 
mutation in the BRCA2 gene (V3091I) was identified in a patient with ampullary 
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carcinoma, which conferred an exceptional response to platinum-containing adjuvant 
regimen [76]. Finally, more recently the same group published a larger scale study in 
which they compared the potential of cfDNA and exoDNA analysis for the 
ultrasensitive identification of mutations of the KRAS gene as biomarker of pancreatic 
ductal adenocarcinoma (PDAC) [82]. In this study, exoDNA has proven better than 
cfDNA for the detection of mutant KRAS (especially in early stages of disease), and 
better than CA 19-9 (which is currently the only guideline-recommended protein 
biomarker for PDAC[83]) for prognostic stratification [82]. However, mutations in KRAS 
were identified in a significant proportion of healthy donors too, thus indicating that the 
identification of a single genetic mutation as a predictor of PDAC may have low 
predictive value [82].
3. Proximal Samplings: an alternative source of tumor DNA
Proximal sampling consists in the sampling of body fluids different from blood, such 
as urine, saliva, sputum, cerebrospinal fluid (CSF), pleural effusions and stool. These 
fluids have great potential as an alternative or complementary source of tumor DNA 
for liquid biopsy. Their analysis is generally limited to detection of local cancers, with 
the major exception of urine. In these cases the close proximity, if not the direct 
contact, of the diseased organ with the body fluid may increase the yield of tumor DNA 
compared to systemic sources [84]. Another advantage of proximal samplings is that, 
except in the case of inflammation and late stage organ damage, they don’t contain 
immune cells, thus having lower interference by non-tumor DNA [85]. Generally, every 
body fluid has two populations of cell-free DNA: a low molecular weight (MW) 
population derived from circulation and a high MW population derived from exfoliating, 
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apoptotic and necrotic cells [84]. These fluids can be divided into two groups, “non-
invasive” and “invasive”, based on whether their collection is more or less invasive 
relative to blood sampling.
The “non-invasive” group includes urine, saliva, sputum and stool. Their ease of 
collection, which requires little or no participation from healthcare professionals, is an 
important point of strength [84]. Sputum-derived DNA is gaining attention in the context 
of lung cancer diagnosis and patient stratification [86]. The analysis of stool-derived 
DNA has been recently validated as a powerful diagnostic tool of colorectal cancer 
[87] and showed potential in the diagnosis of pancreatic cancer [88]. Urinary DNA has 
great potential as liquid biopsy for several types of cancers including prostate, bladder, 
cervical but also non-urogenital malignancies like NSCLC, colorectal and gastric 
cancer [89]. Finally, saliva is an important source of biomarkers for head and neck 
squamous cell carcinomas (HNSCC) [90]. Interestingly, salivary DNA has also been 
used for the detection of EGFR mutations in NSCLC [91].
The “invasive” group of body fluids mainly includes pleural effusions and cerebrospinal 
fluid (CSF). Malignant pleural effusions are caused by malignant pleural mesothelioma 
(MPM) and lung cancer and the deriving DNA has been used for the detection of these 
pathologies [92, 93]. CSF is set to become an important source of ctDNA for central 
nervous system (CNS)-restricted tumors, overcoming the limitations caused by 
scarcity of ctDNA in the blood of these patients [84]. In a ground-breaking study, De 
Mattos-Arruda et al. demonstrated that CFS ctDNA better represented the genomic 
alterations of brain tumors, including primary tumors and brain metastatic lesions, 
compared to plasma ctDNA [94].
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A further class of body fluids showing potential for liquid biopsy is represented by the 
fluids derived from medical procedures. For example, bronchoalveolar lavage-derived 
DNA has potential for NSCLC diagnosis [95], while uterine lavage has been used to 
identify cancer-associated mutations in patients with early-stage endometrial cancer. 
In this study, high MAFs of cancer driver mutations were observed in patients without 
a cancer diagnosis, suggesting the presence of a premalignant landscape of mutations 
[96].
4. Current limitations of ctDNA analysis
ctDNA analyses possess enormous potential in the early diagnosis of cancer, however 
at this early stage, their capacity to achieve this is limited by detection sensitivity. Early-
stage cancers very often are characterized by a very low amount of ctDNA, resulting 
in a MAF that may be undetected using existing techniques [26]. Approaches to 
improve sensitivity consider proximal samplings, i.e., the use of other body fluids, as 
an alternative or in combination with plasma: for example, urine samples for bladder 
cancer. Other approaches could be the use of in vivo implanted devices containing 
cfDNA-binding materials, with the aim of increasing the yield of cfDNA without the 
need of extensive blood draws. This approach has already been successfully tested 
for CTCs [97]. 
Another challenge for early diagnosis of cancer relies in the fact that the identified 
mutations need to have a high predictive value. Single or small panels of mutations 
may not be predictive of cancer, as it has been shown that cancer-associated 
mutations can be present in plasma of healthy individuals [26, 82]. In order to improve 
predictive capacity, other biomarkers should also be considered as part of the 
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analysis. The CancerSEEK platform for instance is a multi-analyte blood test recently 
described by Cohen et al. capable of detecting eight different types of cancer through 
a combined analysis of 8 proteins and genetic mutations in ctDNA, achieving a 
sensitivity between 69 - 98% basing on the type of cancer and, most importantly, a 
specificity of >99% [98]. A different approach for early detection being trialled is the 
“The Circulating Cell-free Genome Atlas Study”, a large prospective, multi-center, 
observational study which aims at using deep genome-wide sequencing of circulating 
nucleic acids in order to develop computational models for distinguishing cancer from 
non-cancer specimens, thus enabling early diagnosis. The first results of this trial 
showed encouraging results for the early diagnosis of lung cancer [99]. This approach 
could also benefit, in the future, of machine learning as a strategy to detect tumor 
biomarker “signatures” [100].
A last important factor to be considered in improving the quality of ctDNA analysis is 
the pre-analytical handling of blood samples [101], especially with regards to the 
purification of ctDNA from whole blood. Current ctDNA isolation procedures involve 
the shipment of the blood sample to central laboratories, separation of plasma by 
centrifugation and ctDNA purification from plasma. These procedures are complex and 
time consuming and require intense handling of the samples, which can result in 
ctDNA degradation (resulting in a drop in mutant allele concentration) or in the release 
of genomic wild-type DNA caused by the lysis of blood cells (resulting in a drop of 
mutant allele fraction) [26]. Although blood samples could be stabilized by different 
types of specialized blood collection tubes [102], it would be advantageous to perform 
ctDNA purification on-site, right after the blood draw, minimizing the number of steps 
requiring handling of the sample and the overall time needed for purification. In order 
to achieve this goal, Kim and colleagues have developed a fully automated lab-on-a-
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disc system, which integrates all the steps of ctDNA purification starting from whole 
blood and performs the extraction in 30 minutes. Furthermore, as a proof of its 
applicability, they used this system to isolate ctDNA from NSCLC patients and 
successfully detected EGFR mutations arising after drug therapy [103].
5. Concluding Remarks and Future Directions
The birth of precision oncology, which has been made possible by recent 
advancements in molecular profiling of cancer, has shifted the cancer management 
strategies towards a more and more personalized approach, overcoming the old “one 
size fits all” therapeutic paradigm. Genetic analyses of tumor samples obtained by 
conventional solid tissue biopsies and evaluation of circulating levels of biomarker 
proteins are currently routine for treatment decision and patient stratification and 
prognosis, although both approaches have important limitations. Conventional tissue 
biopsies, in particular, are invasive procedures that don’t allow longitudinal monitoring 
and are not representative of tumor spatial and temporal clonal heterogeneity. As a 
more favourable alternative to tissue biopsies, the concept of “liquid biopsy”, consisting 
in the sampling and analysis of the tumor circulome, is now gaining an exceptional 
momentum. At present ctDNA, including exosome-associated ctDNA, is a promising 
constituent within the tumor circulome for use in liquid biopsies, and this is supported 
by recent FDA approvals. The technologies available for ctDNA characterization allow 
a range of analyses spanning from single gene mutational assessment to next-
generation deep genome sequencing and methylation analysis, and their applicability 
encompass all the stages of cancer management. Despite this, ctDNA use as liquid 
biopsy has still some limitations on which further research should be focused. Its 
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capacity to achieve early detection is limited by detection sensitivity of low blood 
ctDNA concentrations correlating to low tumor burden. The sensitivity of the most 
recent analytical platforms is around 0.02% MAF. Approaches to improve sensitivity 
may involve association between blood and proximal samplings and the use of in vivo 
DNA capture devices. Furthermore, technological advancements such as the use of 
UMIs in the amplification step preceding sequencing and the in vitro / in silico 
enrichment of ctDNA fragments by virtue of their smaller size are also valid 
approaches to enhance the sensitivity. 
Another challenge in early diagnosis of cancer relies in the low predictive value of 
single mutations. To improve predictive capacity, other strategies should also be 
considered including multi-analyte systems, such as the CancerSeek Platform, or the 
use of computational models and machine learning.
Improving of the quality of ctDNA analysis is central to successful application. The pre-
analytical handling of blood samples, including streamlining workflows and protocols 
for optimal purification of ctDNA from biological samples that minimize analyte 
degradation, should be prioritized. Technologies being developed for this purpose 
include fully automated lab-on-a-disc systems, which integrate all the steps of 
purification quickly and effectively. 
Taken together, the studies reviewed here highlight the prominent role played by 
ctDNA in the liquid biopsy field and its enormous potential to change current strategies 
in personalized cancer management. We have also shed light on current limitations in 
this field, giving a hint on where future research should be focused. Numerous clinical 
studies are ongoing, and further studies will be needed, to comprehensively assess 
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the clinical value and applicability of ctDNA, but this exciting new field is already 
revolutionizing the way we diagnose and treat cancer.
Although it is unlikely that ctDNA would replace the golden standards of disease 
diagnosis, prognosis and monitoring in a short timeframe, its analysis already provides 
a valuable complementary approach. This is especially true in cases where available 
disease monitoring methodologies are inadequate, such as when the patient’s health 
status is not compatible with an invasive biopsy.
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ddPCR: Droplet Digital PCR
dPCR: Digital PCR
EV: Extracellular Vesicle
HNSCC: Head and Neck Squamous Cell Carcinoma
MAF: Mutant Allele Fraction
MW: Molecular Weight
NGS: Next-Generation Sequencing
NSCLC: Non-small Cells Lung Cancer
PCR: Polymerase Chain Reaction
PDAC: Pancreatic Ductal Adenocarcinoma
PTM: Post-Translational Modification
qPCR:Qquantitative PCR
TEP: Tumor Educated Platelet
TKI: Tyrosine Kinase Inhibitor
UMI: Unique Molecular Identifier
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FIGURE CAPTIONS
Figure 1 – The Tumor Circulome
The tumor circulome is defined as the set of tumor-derived elements, circulating into 
the bloodstream, which can be used as a direct or indirect source of tumor 
biomarkers and can be obtained with a simple blood draw. It includes nucleic acids 
(ctDNA and RNA), proteins, extracellular vesicles, circulating tumor cells and tumor-
educated platelets. The tumor clonal heterogeneity is indicated in the figure by the 
use of different colours. The advantages of liquid biopsies over conventional tissue 
biopsies are many. First of all, liquid biopsies are non-invasive and therefore allow a 
longitudinal follow-up of the patient. Most importantly, as shown in the figure, the 
content of a liquid biopsy is usually representative of all the different clones 
contributing to the primary tumor and the metastatic lesions, thus allowing for a more 
accurate characterization of the disease. The same representativeness is not 
achievable by conventional tissue biopsy as only a small portion of the tumor is 
sampled.
CTC: Circulating tumor cell; ctDNA: circulating tumor DNA; TEP: Tumor-educated 
platelet
Figure 2 – Technologies used for ctDNA analysis
The technological approaches available for ctDNA analysis range from single locus 
to genome-wide. They allow the identification and quantification of mutations, copy 
number alterations (duplications and deletions), chromosomal translocations and the 
assessment of CpG island methylation patterns. Most of these approaches are 
based either on NGS or PCR and PCR-derivated technologies or on associations 
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between them. With regards to NGS-based approaches, usually the number of loci 
analyzed is inversely proportional to the sensitivity of mutant detection. The 
technologies used for methylation assessment are based on the bisulphite-mediated 
conversion of unmethylated cytosines into uracil and subsequent analysis through 
PCR, NGS, arrays or restriction enzymes. 
ARMS-PCR: Amplification-Refractory Mutation System PCR; Array-CGH: Array-
Comparative Genome Hybridization; BEAM: Beads, Emulsion, Amplification, 
Magnetics; CAPP-Seq: CAncer Personalized Profiling by deep Sequencing; ddPCR: 
Droplet digital PCR; dPCR: Digital PCR; eTAm-Seq: Enhanced Tagged Amplicon 
Sequencing; NAME-PrO: Nuclease-assisted Minor-allele Enrichment with Probe-
Overlap; NGS: Next Generation Sequencing; PARE: Personalized Analysis of 
Rearra nged Ends; PCR: Polymerase Chain Reaction; SiMSen-Seq: Simple, 
multiplexed, PCR-based barcoding of DNA for sensitive mutation detection using 
sequencing; sWGS: Shallow Whole Genome Sequencing; UMI: Unique Molecular 
Identifier; WES: Whole Exome Sequencing.
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Table 1 – Ongoing Interventional Industry-funded clinical studies on ctDNA
Study type / 
Phase
NCT 
Number
Title 
(Acronym)
Description Cancer 
Type(s)
Sponsors / 
Collaborators
Explored 
parameters
Techniques 
/ Platforms
Enrollment 
N.
Status
NCT03302884 Circulating Tumor 
DNA as an Early 
Marker of 
Recurrence and 
Treatment Efficacy 
in Ovarian 
Carcinoma 
(CIDOC)
Evaluation of the 
prognostic value of 
ctDNA levels 
measurement for 
recurrence prediction 
(3 years)
Ovarian 
Carcinoma
Institut Paoli-
Calmettes / 
AstraZeneca
Mutation 
analysis
N/A 150 Not yet 
recruiting
Interventional 
/ N/A
NCT03017183 Detection of 
Heterogeneity in 
Central Lung 
Cancer - EBUS-
TBNA and ctDNA 
Analysis vs. 
Endobronchial 
Forceps Biopsy
Evaluation of the 
Diagnostic Value of 
EBUS-TBNA and 
ctDNA Analysis 
compared to 
conventional forceps 
sampling
Lung Neoplasms Wissenschaftliches 
Institut Bethanien / 
AstraZeneca / 
Institute of 
Pathology, 
University Clinic 
Düsseldorf
Mutation 
analysis 
(multiple 
genes)
N/A 30 Recruiting
NCT02808884 Cancer DNA 
Screening Pilot 
Study (CANDACE)
Evaluation of positive 
and negative 
predicting values (1-2 
years) of a NGS-
based ctDNA assay 
for the early detection 
of cancer
Pan-Cancer British Columbia 
Cancer Agency / 
University of British 
Columbia / 
University of Utah / 
Pathway Genomics 
/ Boreal Genomics
Mutation 
analysis 
(multiple 
genes)
NGS 1000 Active, 
not 
recruiting
Interventional 
/ Phase 1
NCT02510001 MEK and MET 
Inhibition in 
Colorectal Cancer 
(MErCuRIC1)
Includes, among 
secondary outcomes, 
gene sequencing from 
ctDNA in serially 
collected plasma 
samples from mCRC 
patients (1 year) to 
develop a liquid 
biopsy platform for 
routine assessment of 
therapeutic efficacy.
Colorectal 
Cancer
University of 
Oxford / Pfizer / 
European 
Commission / 
Array Biopharma 
and 11 others
Mutation 
analysis 
(multiple 
genes)
NGS 92 Recruiting
NCT02955758 Pembrolizumab in 
Patients With 
Metastatic Non-
squamous Non-
small Cell Lung 
Cancer
Correlation between 
ctDNA levels and 
radiographic tumor 
assessment (RECIST 
v1.1) to investigate 
the effect of 
Pembrolizumab on 
patients with NSCLS 
(2 years)
Metastatic Non-
Squamous Non-
Small Cell Lung 
Carcinoma
Joel Neal / Merck 
Sharp & Dohme 
Corp. / Stanford 
University
Mutation 
analysis 
(multiple 
genes) and 
ctDNA 
concentration
CAPP-Seq 25 RecruitingInterventional 
/ Phase 2
NCT02892734 Ipilimumab and 
Nivolumab in 
Treating Patients 
With Recurrent 
Stage IV HER2 
Negative 
Inflammatory 
Breast Cancer
Includes, among the 
tertiary outcomes, the 
assessment of the 
predictive value of 
exosome-associated 
ctDNA analysis for the 
evaluation of 
treatment response 
using blood samples 
at baseline
Metastatic 
recurrent HER2-
negative 
inflammatory 
breast cancer
Northwestern 
University / Bristol-
Myers Squibb / 
National Cancer 
Institute (NCI)
N/A N/A 29 Recruiting
NCT02997501 T790M Plasma 
Testing 
Methodology 
Comparison and 
Clinical Validation 
(ADELOS)
Evaluation of the 
concordance between 
the Cobas test and 
three other platforms - 
Evaluation of 
sensitivity and 
specificity of the three 
platforms in 
comparison with the 
cobas test
Non-Small Cell 
Lung Carcinoma
AstraZeneca / 
TigerMed
Mutation 
analysis 
(single gene)
Cobas v2 
EGFR test
Super-ARMS
dPCR
NGS
167 Active, 
not 
recruiting
Interventional 
/ Phase 3
NCT03038217 Investigation of the 
Value of ctDNA in 
Diagnosis, 
Treatment, and 
Surveillance of 
Surgically 
Resectable 
Colorectal Cancer
Determination of the 
value of circulating 
tumor DNA (ctDNA) 
analysis in predicting 
the therapeutic effects 
of combined and 
surgical treatments 
and the long-term (5 
years) prognosis.
Rectal Cancer, 
Adenocarcinoma
gwcmc / Geneplus-
Beijing Co. Ltd.
Mutation 
analysis
NGS 300 Not yet 
recruiting
NCT03439046 Study of the 
Molecular Features 
of Postmenopausal 
Women With HR+ 
HER2-negative 
aBC on First-line 
Treatment With 
Ribociclib and 
Letrozole 
(BioItaLEE)
Evaluation of the 
molecular features of 
postmenopausal 
women with hormone 
receptor-positive, 
HER2-negative 
advanced breast 
cancer on first-line 
treatment with 
ribociclib and 
letrozole. Includes 
associations of the 
identified mutational 
landscape with 
treatment response  
Advanced 
Breast Cancer
Novartis 
Pharmaceuticals
Mutation 
analysis 
(multiple gene)
ctDNA 
concentration
N/A 350 Not yet 
recruiting
NCT03079011 PAlbociclib and 
Circulating Tumor 
DNA for ESR1 
Mutation Detection 
(PADA-1)
Evaluation of the 
efficacy of a change of 
the hormone therapy 
(from aromatase 
inhibitor to fulvestrant) 
associated with 
palbociclib driven by 
the identification of 
ESR1 mutants in 
ctDNA
Metastatic 
Breast Cancer
UNICANCER / 
Pfizer
Mutation 
analysis 
(single gene)
N/A 800 Recruiting
The indicated details about the clinical studies have been obtained from the NIH clinical trials server (https://clinicaltrials.gov/) – 
Last visit: 06/07/2018
EBUS-TBNA: Endobronchial Ultrasound-guided Transbronchial Needle Aspirate; N/A: Information not available on the study’s 
corresponding page; RECIST: Response Evaluation Criteria in Solid Tumors – International guidelines for tumor response 
assessment published by the World Health Organization.
Table 2 – Ongoing Observational Industry-funded clinical studies on ctDNA
Study type NCT 
Number
Title 
(Acronym)
Description Cancer 
Type(s)
Sponsor / 
Collaborators
Explored 
parameter(s)
Technique(s) 
/ Platform(s)
Enrollment 
N.
Status
NCT03085888 The STRIVE 
Study: Breast 
Cancer 
Screening 
Cohort
Training and 
validation of an 
assay to detect 
early breast 
cancer: 120,000 
women undergoing 
screening 
mammography will 
be subjected to 
blood draw and 
extensive 
sequencing of 
ctDNA and other 
circulating tumor 
derived nucleic 
acids.
Breast Cancer GRAIL, Inc. Mutation 
analysis 
(multiple genes)
High-Intensity 
whole genomic 
sequencing 
(NGS)
Machine 
Learning
120000 Enrolling 
by 
invitation
NCT03483922 HCC Screening 
Using DNA 
Methylation 
Changes in 
ctDNA
Development of a 
test based on the 
assessment of 
methylation 
profiles on ctDNA 
and PBMC and T 
Cell-derived DNA 
for the early 
detection of the 
transition from 
Chronic Hepatitis 
B to Hepatocellular 
Carcinoma
Hepatocellular 
Carcinoma
HKGepitherapeutics 
/ International 
Centre for 
Diarrhoeal Disease 
Research, 
Bangladesh
ctDNA 
methylation 
(multiple genes)
Bisulphite 
Conversion + 
NGS
400 Recruiting
Observational 
NCT03519958 Epidermal 
Growth Factor 
Receptor 
(EGFR) T790M 
Mutation Testing 
Practices in 
Hong Kong
Study of the EGFR 
T790M mutation 
prevalence in 
ctDNA and urinary 
ctDNA of NSCLC 
patients who 
progressed after 
previous TKI 
treatment.
Non-small Cell 
Lung Cancer
AstraZeneca Mutation 
analysis (single 
gene)
ddPCR 100 Not yet 
recruiting
NCT03517332 Circulating 
Tumor DNA 
Exposure in 
Peripheral Blood
Test of the 
feasibility of using 
an innovative 
approach for 
ctDNA detection 
for the diagnosis of 
different types of 
tumors. Patients 
recruited must 
have a cancer 
diagnosis and 
must not have 
been treated yet.
Different 
Types
Quantgene Inc. Mutation 
analysis 
(multiple genes)
N/A 10000 Recruiting
NCT02994511 Cambridge 
Liquid Biopsy 
and Tumor 
Profiling Study 
for Patients on 
Experimental 
Therapeutics 
Trials 
(CALIBRATE)
Investigation of the 
potential of ctDNA 
as a predictive 
factor of resistance 
or response to 
anticancer 
treatment.
Different 
Types
CCTU- Cancer 
Theme / 
AstraZeneca / 
Cambridge 
University Hospitals 
NHS Foundation 
Trust
ctDNA 
concentration
Mutation 
analysis 
(multiple genes), 
genomic profile
NGS 100 Recruiting
NCT02889978 The Circulating 
Cell-free 
Genome Atlas 
Study
Development of 
computational 
models for 
distinguishing 
cancer from non-
cancer specimens, 
thus enabling early 
diagnosis
Pan-Cancer GRAIL, Inc. Mutation 
analysis 
(multiple genes, 
whole genome)
Methylation 
analysis
High-Intensity 
Sequencing 
(NGS)
Whole Genome 
Bisulphite 
Sequencing
Machine 
Learning
15000 Recruiting
NCT02284633 Blood Sample 
Monitoring of 
Patients With 
EGFR Mutated 
Lung Cancer
Study of the 
evolution of EGFR 
mutational 
landscape and 
correlation with 
resistance to first 
line treatment and 
Progression Free 
Survival. Early 
identification of 
disease 
progression. 
Non-Small 
cells Lung 
Cancer
Aarhus University 
Hospital / Odense 
University Hospital / 
Aalborg 
Universitetshospital 
/ Herning Hospital / 
Roche Pharma AG
Mutation 
analysis (single 
gene)
qPCR (cobas) 200 Recruiting
The indicated details about the clinical studies have been obtained from the NIH clinical trials server (https://clinicaltrials.gov/) – 
Last visit: 06/07/2018
HCC: Hepatocellular Carcinoma; N/A: Information not available on the study’s corresponding page; PBMC: Peripheral Blood 
Mononuclear Cell.
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